Diagnostic Value of Serum Tumor Markers in Skeletal Metastasis of Carcinomas

Overview

Journal Arch Orthop Trauma Surg

Specialties Emergency Medicine
General Surgery
Orthopedics

Date 1990 Jan 1

PMID 1702981

Authors

M Chigira

T Shinozaki

Affiliations

Soon will be listed here.

Abstract

Levels of serum tumor markers including tissue polypeptide antigen (TPA), CA 15-3, CA 19-9, squamous cell carcinoma antigen, carcinoembryonic antigen, alpha-fetoprotein, and PAP were measured in 26 patients with bone metastasis and in 9 patients with primary bone tumors. More than one markers was elevated in 19 of the 26 patients with bone metastasis, although there was no elevation of the markers in 3 patients with renal cell carcinoma. TPA was the most sensitive marker in the diagnosis of metastasis. CA 15-3 was also a sensitive marker in this study, since metastasis from breast carcinoma may be the most common of all metastases in the skeleton. On the other hand, alpha-fetoprotein was uniformly unresponsive except in one case of gastric cancer. Combinations of markers are valuable for metastasis screening tests. No definite correlations were found between the markers in this study. On the other hand, there was a slight elevation of the markers observed in two of the nine patients with primary bone lesions. Serum tumor markers are useful in the diagnosis of bone metastasis to differentiate it from primary bone lesions. Especially in solitary bone lesions, serum markers may be the only way to make a differential diagnosis between the two.

References

Campanacci M, Bacci G, Pagani P, Giunti A . Multiple-drug chemotherapy for the primary treatment of osteosarcoma of the extremities. J Bone Joint Surg Br. 1980; 62-B(1):93-101. DOI: 10.1302/0301-620X.62B1.6927980. View

Basso D, Fabris C, Del Favero G, Panucci A, Plebani M, Angonese C . Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?. Oncology. 1988; 45(1):24-9. DOI: 10.1159/000226525. View

Didolkar M, Fanous N, Elias E, Moore R . Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg. 1977; 186(5):625-30. PMC: 1396304. DOI: 10.1097/00000658-197711000-00014. View

Nather A, Bose K . The results of decompression of cord or cauda equina compression from metastatic extradural tumors. Clin Orthop Relat Res. 1982; (169):103-8. View

Panucci A, Fabris C, Del Favero G, Basso D, Di Mario F, Marchioro L . Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?. J Clin Pathol. 1986; 39(1):75-7. PMC: 499616. DOI: 10.1136/jcp.39.1.75. View

Koch M, McPherson T . Carcinoembryonic antigen levels as an indicator of the primary site in metastatic disease of unknown origin. Cancer. 1981; 48(5):1242-4. DOI: 10.1002/1097-0142(19810901)48:5<1242::aid-cncr2820480531>3.0.co;2-q. View

MOERTEL C, Reitemeier R, SCHUTT A, Hahn R . Treatment of the patient with adenocarcinoma of unknown origin. Cancer. 1972; 30(6):1469-72. DOI: 10.1002/1097-0142(197212)30:6<1469::aid-cncr2820300609>3.0.co;2-t. View

Thomson D, KRUPEY J, Freedman S, Gold P . The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A. 1969; 64(1):161-7. PMC: 286141. DOI: 10.1073/pnas.64.1.161. View

Sherry H, Levy R, Siffert R . Metastatic disease of bone in orthopedic surgery. Clin Orthop Relat Res. 1982; (169):44-52. View

10.

Putzki H, Student A, Jablonski M, Heymann H . Comparison of the tumor markers CEA, TPA, and CA 19-9 in colorectal carcinoma. Cancer. 1987; 59(2):223-6. DOI: 10.1002/1097-0142(19870115)59:2<223::aid-cncr2820590208>3.0.co;2-b. View

11.

Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M . Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies. Digestion. 1985; 31(2-3):67-76. DOI: 10.1159/000199182. View

12.

Schocker J, BRADY L . Radiation therapy for bone metastasis. Clin Orthop Relat Res. 1982; (169):38-43. View

13.

Del Villano B, Brennan S, Brock P, Bucher C, Liu V, McClure M . Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983; 29(3):549-52. View

14.

JOHNSTON A . Pathology of metastatic tumors in bone. Clin Orthop Relat Res. 1970; 73:8-32. View

15.

SCHAJOWICZ F, McGuire M . Diagnostic difficulties in skeletal pathology. Clin Orthop Relat Res. 1989; (240):281-310. View

16.

Kato H, Torigoe T . Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977; 40(4):1621-8. DOI: 10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435>3.0.co;2-i. View

17.

SUTOW W, Gehan E, Vietti T, Frias A, Dyment P . Multidrug chemotherapy in pulmonary treatment of osteosarcoma. J Bone Joint Surg Am. 1976; 58(5):629-33. View

18.

Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U . Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Bull Cancer. 1986; 73(3):251-5. View

19.

Hayakawa T, Kondo T, Shibata T, Hamano H, Kitagawa M, Sakai Y . Sensitive serum markers for detecting pancreatic cancer. Cancer. 1988; 61(9):1827-31. DOI: 10.1002/1097-0142(19880501)61:9<1827::aid-cncr2820610918>3.0.co;2-8. View

20.

Del Favero G, Fabris C, Plebani M, Panucci A, Piccoli A, Perobelli L . CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer. 1986; 57(8):1576-9. DOI: 10.1002/1097-0142(19860415)57:8<1576::aid-cncr2820570823>3.0.co;2-9. View